NGL FINECHEM
|
The Current P/E Ratio of NGL FINECHEM is 26.85.
Share Price | ₹1,792.4 | Nov 19,2024 |
Market Cap | ₹1,111.3 Cr | |
Earnings-TTM | ₹41.4 Cr | TTM-Consolidated Results |
Price/Earnings | 26.85x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of NGL FINECHEM
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹1,111.3 Cr] as on Nov 19,2024
(/) Earnings [ ₹41.4 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 26.85x ]
Thus, for NGL FINECHEM , the investors are currently willing to pay 26.85 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NGL FINECHEM !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NGL FINECHEM over the last five years.
Historical PE (Price/Earnings) ratio chart of NGL FINECHEM
PE Ratio Performance Analysis for NGL FINECHEM
- NGL FINECHEM 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 25.58x.
- NGL FINECHEM 's operated at median p/e ratio of 24.27x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NGL FINECHEM 's p/e ratio peaked in Mar2023 at 36.22x.
- NGL FINECHEM 's p/e ratio hit its five-year low in Mar2021 of 16.74x.
How does NGL FINECHEM 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
NGL FINECHEM | 41.39 | 26.85 | 1,111.3 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,136.50 | 38.25 | 425,930.0 |
CIPLA LTD | 4,485.22 | 26.49 | 118,828.0 |
DR REDDYS LABORATORIES LTD | 5,406.80 | 18.73 | 101,290.0 |
ZYDUS LIFESCIENCES LTD | 4,298.90 | 22.16 | 95,280.3 |
DIVIS LABORATORIES LTD | 1,836.00 | 85.25 | 156,524.0 |
MANKIND PHARMA LTD | 2,124.86 | 48.42 | 102,890.0 |
TORRENT PHARMACEUTICALS LTD | 1,802.00 | 58.13 | 104,742.0 |
LUPIN LTD | 2,651.94 | 35.04 | 92,929.7 |
AUROBINDO PHARMA LTD | 3,598.83 | 20.14 | 72,478.2 |
ABBOTT INDIA LTD | 1,284.66 | 44.98 | 57,784.9 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NGL FINECHEM 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 18.73x |
Max industry PE | 85.25x |
Median industry PE | 35.04x |
Average industry PE | 38.59x |
You may also like the below Video Courses